Rifle scope designs follow trends in the rifles that they’ll be paired with. The 3-9×42 scope, one of the best all-around hunting optics mounted on generations of bolt-action rifles, held sway until ...

That’s a fair perspective, and one that I shared as a beginning hunter who sweated a little to spend $300 for a Leupold VX-3 back in 1990. But we picked $500 as the cap for our budget rifle scope ...

Without question, these modern day optics are the best scopes for .30-30 rifles that hunters have ever had at their disposal. A 3-9X rifle scope with a 1-inch tube has been the gold standard for ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

The last time I wrote about Viridian Therapeutics, Inc. (VRDN) it was in a Seeking Alpha article entitled “Viridian: Despite Drop, Advancement Towards Phase 3 continues.” At that time ...

Viridian Therapeutics (NASDAQ:VRDN) added ~26% to reach the highest level since March on Tuesday as Wall Street reacted to topline results from its THRIVE Phase 3 clinical trial for its lead ...

The M151 Improved Spotting Scope allows recognition and identification of targets at long distances for U.S. troops executing precision ground engagements. A light and compact scope with powerful ...

Viridian Therapeutics said Tuesday that an experimental treatment improved the signs and symptoms of thyroid eye disease — results that achieved the primary goals of a Phase 3 clinical trial and ...

Please verify your email address. The Viridian Amber Medallion +3 is a Talisman introduced in Elden Ring: Shadow of the Erdtree. A medallion with viridian amber inlaid. Boosts maximum stamina by ...

Derek Archila has given his Buy rating due to a combination of factors including the promising data from Viridian Therapeutics’ Phase 3 trials for Veligrotug (veli). The data showed that veli ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...